UK 356618 is primarily utilized in the field of medical research, particularly in the study of cardiovascular diseases. It functions as a potent and selective antagonist for the CXCR2 receptor, which plays a significant role in inflammation and immune responses. By inhibiting this receptor, UK 356618 helps researchers investigate the mechanisms underlying inflammatory conditions such as atherosclerosis, chronic obstructive pulmonary disease (COPD), and other inflammatory disorders. Its application in preclinical studies aids in the development of potential therapeutic strategies targeting CXCR2-mediated pathways, offering insights into reducing inflammation and improving outcomes in related diseases.